Spearhead Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-2,151
| Closed | -$314K | – | 103 |
|
|
2022
Q2 | $314K | Sell |
2,151
-26
| -1% | -$3.8K | 0.05% | 118 |
|
|
2022
Q1 | $355K | Sell |
2,177
-905
| -29% | -$148K | 0.04% | 112 |
|
|
2021
Q4 | $523K | Buy |
3,082
+165
| +6% | +$28K | 0.06% | 97 |
|
|
2021
Q3 | $551K | Buy |
2,917
+88
| +3% | +$16.6K | 0.07% | 85 |
|
|
2021
Q2 | $480K | Buy |
2,829
+402
| +17% | +$68.2K | 0.07% | 107 |
|
|
2021
Q1 | $343K | Buy |
2,427
+308
| +15% | +$43.5K | 0.05% | 130 |
|
|
2020
Q4 | $275K | Buy |
2,119
+96
| +5% | +$12.5K | 0.04% | 146 |
|
|
2020
Q3 | $295K | Buy |
2,023
+117
| +6% | +$17.1K | 0.06% | 133 |
|
|
2020
Q2 | $282K | Buy |
+1,906
| New | +$282K | 0.06% | 112 |
|